Emergency intubations: A critical decision with potentially life-altering consequences. A recent study published in the New England Journal of Medicine has shed light on a crucial choice doctors face when intubating critically ill patients: which sedative to use. The Randomized Trial of Sedative Choice for Intubation (RSI) has made a significant impact.
The study compared two commonly used sedatives, etomidate and ketamine, during the process of inserting a breathing tube. The trial, conducted across 14 emergency departments and intensive care units in the U.S., involved 2,365 patients. The findings? Etomidate emerged as the safer option, showing a significant decrease in the risk of dangerously low blood pressure during the procedure, a risk more associated with ketamine.
"We know that patients receive treatments every day in hospitals around the world that have never been evaluated in a rigorous study and may be ineffective or even harmful," stated lead author Dr. Jonathan Casey, emphasizing the importance of such studies.
But here's where it gets controversial... Historically, etomidate was the go-to sedative. However, concerns about its potential to impair cortisol production led some countries to remove it from the market. This opened the door for ketamine to take center stage. This shift is part of a broader trend of using ketamine for an increasing number of conditions, including pain, depression, and PTSD.
The RSI trial, led by Dr. Casey, Dr. Brian Driver, and Dr. Matthew Prekker, provides crucial new evidence. The study demonstrated that etomidate is safe and that ketamine can, in some situations, cause significant drops in blood pressure during intubation.
Dr. Driver explains that "Despite their widespread use, no large, multi-center trial had ever directly compared the two to determine which medication leads to better outcomes for patients until the RSI trial." This research highlights the necessity of studying treatments already in routine use.
And this is the part most people miss... The study's findings may influence countries that previously removed etomidate from the market to reconsider its availability. The results were presented at the Critical Care Reviews conference in Melbourne, Australia – a country where etomidate had been removed.
For the future, researchers are now looking into the long-term effects of these sedatives on patient outcomes, like PTSD symptoms. Additionally, Hennepin Healthcare is leading another trial (BREATHE) to explore the benefits of using smaller breathing tubes to prevent vocal cord injuries.
The RSI trial was funded by the Patient-Centered Outcomes Research Institute and the National Institutes of Health.
What do you think? Do you believe that this study will change the way emergency intubations are handled? Do you have any experience or thoughts on the use of these sedatives? Share your opinions in the comments below!
